Robbins Geller Rudman & Dowd LLP Files Class
Action Suit against XenoPort, Inc.
July 28, 2010 02:50 PM Eastern Daylight Time
SAN DIEGO--(EON: Enhanced Online News)--Robbins Geller Rudman & Dowd LLP (“Robbins Geller”)
(http://www.rgrdlaw.com/cases/xenoport/) today announced that a class action has been commenced in the United
States District Court for the Northern District of California on behalf of purchasers of XenoPort, Inc. (“XenoPort”)
(NASDAQ:XNPT) common stock during the period between May 5, 2009 and February 17, 2010 (the “Class
If you wish to serve as lead plaintiff, you must move the Court no later than 60 days from today. If you wish to
discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s
counsel, Darren Robbins of Robbins Geller at 800/449-4900 or 619/231-1058, or via e-mail at email@example.com.
If you are a member of this class, you can view a copy of the complaint as filed or join this class action online at
http://www.rgrdlaw.com/cases/xenoport/. Any member of the putative class may move the Court to serve as lead
plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
The complaint charges XenoPort and certain of its officers and directors with violations of the Securities Exchange
Act of 1934. XenoPort is a biopharmaceutical company focused on developing a portfolio of internally discovered
product candidates that utilize the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of
The complaint alleges that during the Class Period, defendants publicized misleading and incomplete information
about XenoPort’s Phase 3 clinical program for an extended-release tablet and development stage drug called
Horizant (gabapentin enacarbil), also known as XP13512 (“512”), as a potential treatment for moderate-to-severe
primary Restless Legs Syndrome (“RLS”), including that there was strong evidence of safety and indicating that it
remained on track, creating an opportunity for the Company to raise money. However, the Company’s top
management was aware that 512 had earlier shown an increased occurrence of pancreatic cancer in lab rats. While
the drug had nonetheless been approved for more serious indications, this presented a risk that the FDA would not
approve 512 for less serious maladies given the devastating impact of pancreatic cancer. Instead of disclosing these
findings, which would have affected the public’s expectations about the likelihood of FDA approval, defendants
repeatedly assured the public as to 512’s safety and efficacy. As a result of these false and misleading statements,
XenoPort stock traded at artificially inflated prices during the Class Period, reaching a high of $24.75 per share on
September 17, 2009 and permitting the Company to complete a secondary offering in July 2009 of 2.875 million
shares of XenoPort stock at $19 per share for proceeds of nearly $45 million.
On February 17, 2010, defendants publicly disclosed that the FDA had declined approval of Horizant, with
concerns about laboratory results showing pancreatic cell tumors in rats as a result of the use of the drug. On this
news, XenoPort’s stock fell $12.93 per share to close at $6.67 per share on February 18, 2010 – a one-day
decline of 65% on volume of 36.5 million shares, over 16 times the average three-month daily volume.
Plaintiff seeks to recover damages on behalf of all purchasers of XenoPort common stock during the Class Period
(the “Class”). The plaintiff is represented by Robbins Geller, which has expertise in prosecuting investor class actions
and extensive experience in actions involving financial fraud.
Robbins Geller, a 180-lawyer firm with offices in San Diego, San Francisco, New York, Boca Raton, Washington,
D.C., Philadelphia and Atlanta, is active in major litigations pending in federal and state courts throughout the United
States and has taken a leading role in many important actions on behalf of defrauded investors, consumers, and
companies, as well as victims of human rights violations. The Robbins Geller Web site (http://www.rgrdlaw.com) has
more information about the firm.
Robbins Geller Rudman & Dowd LLP
Darren Robbins, 800-449-4900 or 619-231-1058